Stocks
Avanos Medical Financial Statements (AVNS) |
||||||||||
| Avanos Medicalsmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 19.02.2021 | 23.02.2022 | 31.12.2022 | 21.02.2023 | 21.02.2024 | 02.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 714.8 | 744.6 | 820.0 | 820.0 | 673.3 | 680.1 | |||
| Operating Income, bln rub | -46.1 | 8.90 | 74.0 | 74.0 | 52.4 | 28.7 | ||||
| EBITDA, bln rub | ? | -2.00 | 47.4 | 122.9 | 122.9 | 98.5 | 75.5 | |||
| Net profit, bln rub | ? | -27.2 | 6.30 | 50.5 | 50.5 | -61.8 | -62.2 | |||
| OCF, bln rub | ? | -2.50 | 87.3 | 90.9 | 90.9 | 32.4 | 31.2 | |||
| CAPEX, bln rub | ? | 20.2 | 21.0 | 19.3 | 19.3 | 17.8 | 17.9 | |||
| FCF, bln rub | ? | -22.7 | 66.3 | 71.6 | 71.6 | 14.6 | 13.3 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 419.4 | 355.4 | 376.0 | 376.0 | 330.3 | 356.8 | ||||
| Cost of production, bln rub | 341.5 | 380.3 | 370.0 | 370.0 | 290.6 | 294.6 | ||||
| R&D, bln rub | 34.9 | 32.3 | 30.6 | 30.6 | 27.2 | 26.7 | ||||
| Interest expenses, bln rub | 15.6 | 3.30 | 10.00 | 10.00 | 15.0 | 14.6 | ||||
| Assets, bln rub | 1 673 | 1 595 | 1 787 | 1 787 | 1 692 | 1 661 | ||||
| Net Assets, bln rub | ? | 1 257 | 1 264 | 1 291 | 1 291 | 1 236 | 1 228 | |||
| Debt, bln rub | 248.8 | 187.5 | 280.0 | 280.0 | 209.1 | 214.7 | ||||
| Cash, bln rub | 111.5 | 118.5 | 127.7 | 127.7 | 87.7 | 75.8 | ||||
| Net debt, bln rub | 137.3 | 69.0 | 152.3 | 152.3 | 121.4 | 138.9 | ||||
| Ordinary share price, rub | 45.9 | 34.7 | 27.1 | 27.1 | 22.4 | 21.5 | ||||
| Number of ordinary shares, mln | 47.8 | 48.1 | 46.9 | 46.9 | 46.6 | 46.2 | ||||
| Market cap, bln rub | 2 193 | 1 668 | 1 269 | 1 269 | 1 045 | 995 | ||||
| EV, bln rub | ? | 2 330 | 1 737 | 1 421 | 1 421 | 1 167 | 1 134 | |||
| Book value, bln rub | 296 | 321 | 221 | 221 | 201 | 200 | ||||
| EPS, rub | ? | -0.57 | 0.13 | 1.08 | 1.08 | -1.33 | -1.35 | |||
| FCF/share, rub | -0.47 | 1.38 | 1.53 | 1.53 | 0.31 | 0.29 | ||||
| BV/share, rub | 6.20 | 6.68 | 4.71 | 4.71 | 4.31 | 4.33 | ||||
| EBITDA margin, % | ? | -0.28% | 6.37% | 15.0% | 15.0% | 14.6% | 11.1% | |||
| Net margin, % | ? | -3.81% | 0.85% | 6.16% | 6.16% | -9.18% | -9.15% | |||
| FCF yield, % | ? | -1.04% | 3.98% | 5.64% | 5.64% | 1.40% | 1.34% | |||
| ROE, % | ? | -2.16% | 0.50% | 3.91% | 3.91% | -5.00% | -5.07% | |||
| ROA, % | ? | -1.63% | 0.40% | 2.83% | 2.83% | -3.65% | -3.74% | |||
| P/E | ? | -80.6 | 264.7 | 25.1 | 25.1 | -16.9 | -16.0 | |||
| P/FCF | -96.6 | 25.2 | 17.7 | 17.7 | 71.6 | 74.8 | ||||
| P/S | ? | 3.07 | 2.24 | 1.55 | 1.55 | 1.55 | 1.46 | |||
| P/BV | ? | 7.40 | 5.19 | 5.75 | 5.75 | 5.21 | 4.97 | |||
| EV/EBITDA | ? | -1 165 | 36.6 | 11.6 | 11.6 | 11.8 | 15.0 | |||
| Debt/EBITDA | -68.7 | 1.46 | 1.24 | 1.24 | 1.23 | 1.84 | ||||
| R&D/CAPEX, % | 172.8% | 153.8% | 158.5% | 158.5% | 152.8% | 149.2% | ||||
| CAPEX/Revenue, % | 2.83% | 2.82% | 2.35% | 2.35% | 2.64% | 2.63% | ||||
| Avanos Medical shareholders | ||||||||||
